Lung transplant in Turkey

Türkiye's reputation in transplantation rests on living donation. Faced with a low deceased donation rate, Turkish surgeons built living-donor kidney and liver programmes at a scale few countries match, and international patients who can bring a related donor travel there in significant numbers each year.

That model has no lung equivalent in routine practice. Lung transplantation depends almost entirely on deceased donors, and those organs enter a national allocation system rather than being available to a hospital and its patient.

The confusion this causes is understandable. A family reads that Türkiye is a leading transplant destination, which is true, and assumes it applies to every organ. The openness of the Turkish pathway is a consequence of living donation specifically, and it does not transfer to a procedure where living donation is not an established route.

There is a second reason lungs are different, and it compounds the first. Even in countries with strong deceased donation programmes, lungs are recovered from only a minority of consented donors, because the organ is so vulnerable to the events surrounding death and to intensive care itself. A national list under pressure and a donor pool narrower than for any other organ is not a combination that leaves room for visitors.

What Turkish medicine does offer people with advanced lung disease is worth taking seriously. Interstitial lung disease, bronchiectasis, severe COPD and pulmonary hypertension are all managed at specialist centres. Pulmonary rehabilitation programmes exist. Diagnostic uncertainty — which is common in interstitial disease and materially changes treatment — can be resolved with expert review of imaging and, where indicated, biopsy.

For somebody who has been told they need a transplant, an accurate diagnosis and optimised treatment can change the timeline substantially, and occasionally changes the conclusion. That is a legitimate reason to seek an opinion abroad; a place on the list is not.

Three separate questions get collapsed into one, and separating them makes the answer clearer: do you need a transplant, could you have one here, and is there something else worth travelling for.

The second has been answered, and it does not turn on how unwell you are or what you can pay. There is no organ available to allocate to you.

The first is worth genuine attention, because it is not always settled. Interstitial lung disease in particular is a family of conditions that look alike on a report and behave very differently, and the distinction between them changes both treatment and prognosis. Expert re-reading of high-resolution CT, sometimes with a multidisciplinary discussion involving a radiologist and a pathologist, changes the diagnosis in a meaningful minority of referred cases. If your diagnosis was made without that, a second opinion is reasonable regardless of transplantation.

The third question — what else is available — has better answers than most people expect. Antifibrotic treatment for progressive fibrosis, proper management of bronchiectasis including airway clearance and targeted antibiotics, pulmonary hypertension therapy, treatment of reflux and sleep-disordered breathing, and nutritional support all affect how fast disease progresses. Pulmonary rehabilitation improves function and survival, and it is undersupplied almost everywhere.

Selected patients with emphysema may be candidates for lung volume reduction, either surgically or by endobronchial valves, which is a genuine alternative rather than a consolation. Somebody with a large bulla may benefit from bullectomy. These are decisions requiring careful assessment, but they are decisions Turkish thoracic units can make and act on.

And if you are listed at home, the strongest advice is usually to stay listed. Waiting time is not portable, and leaving a list to pursue an option abroad can cost a position that took a long time to reach.

For a second opinion or an assessment of non-transplant options, the review begins with documents, and sending them well is the difference between a useful answer within days and a vague one after weeks.

Send full pulmonary function tests with the actual numbers, including lung volumes and gas transfer, not merely the interpretation. Send arterial blood gases if they have been taken. Send high-resolution CT of the chest as images on disc rather than only as a report, because in interstitial disease the images are the diagnosis and a second reader needs to see them.

Send a six-minute walk test result with oxygen saturation, an echocardiogram, and a right heart catheterisation report if pulmonary hypertension has been suspected or measured. Send sputum culture results, especially any resistant organisms, non-tuberculous mycobacteria or fungi, because these change what any team would advise.

Include a clear chronological history: when symptoms began, what the diagnosis was and how it was reached, what treatment has been tried and what happened, oxygen requirement now, and how many admissions there have been. A summary letter from your respiratory physician is worth more than a stack of results.

If a lung biopsy was performed, send the pathology report and, if possible, arrange for slides to be available for review. Reclassification on review is common enough that it is worth the effort.

Translate everything into English or Turkish before sending. Untranslated records are the single commonest reason a remote review stalls, and translation costs a fraction of a wasted trip.

Hospitals recorded on this platform are taken from public references rather than marketing claims. A hospital appearing here does not indicate that it can transplant lungs into an international patient — none can. What these centres can be asked about is diagnosis, medical treatment, thoracic surgery and rehabilitation. The questions that separate a serious unit from a sales department are how many of your specific procedure they perform annually, whether their interstitial disease cases go through a multidisciplinary discussion, and who will manage your care after you return home.

Names shown are linked to their current recorded hospital affiliations and update when those change. Inclusion records an affiliation rather than a personal recommendation, and the choice of clinician is between you and the centre once your records have been read.

Because transplantation is not available, the stay to plan for is the one that is: assessment, medical treatment, or thoracic surgery. These are shorter and far more predictable than a transplant.

A diagnostic assessment usually needs several days rather than weeks. Lung function testing, imaging, walk testing, echocardiography and clinic reviews can generally be arranged within a single week if scheduled in advance, and much of the preparatory review can happen remotely before you fly.

If a bronchoscopy or biopsy is proposed, allow additional days and expect a short recovery, and be aware that pathology takes time — results may follow you home rather than arrive before you leave. Agree in advance how those results will be communicated and to whom.

Lung volume reduction, whether by valves placed at bronchoscopy or by surgery, requires a longer stay. Valve placement involves several days of inpatient observation because of the risk of pneumothorax; surgery requires chest drains and a recovery measured in a couple of weeks. Do not book a return flight tightly around either.

Flying with advanced lung disease is itself a clinical question. Cabin pressure reduces available oxygen, and somebody marginal at sea level may need in-flight oxygen, which airlines require to be arranged in advance with medical documentation. Ask your own respiratory physician before booking, and ask specifically about a hypoxic challenge test if you use oxygen or are close to needing it.

Accommodation near the hospital matters because appointments cluster, and a companion is worth having for anybody whose exercise tolerance is limited. Book somewhere extendable: complications and pathology delays both stretch trips.

Travelling to Türkiye for respiratory assessment or treatment is straightforward logistically, and the planning is the same as for any significant medical trip.

Visa requirements differ substantially by nationality — some travellers need nothing in advance, others an electronic authorisation, others a consular appointment that can take weeks. Begin that process alongside the medical review rather than after it, and ask the hospital for an invitation letter stating the purpose and expected duration of the visit.

Fitness to fly deserves a separate conversation with your own physician. This is not a formality for somebody with advanced lung disease: reduced cabin oxygen can cause real problems, and arranging supplemental oxygen requires notice, documentation and often a fee. Airlines have different policies about concentrators, and battery requirements are specific.

Bring a companion if your exercise tolerance is limited. Airports involve more walking than people anticipate, and assistance should be booked in advance rather than requested on the day.

Carry medication in hand luggage in original packaging with a letter listing doses, and bring more than the trip requires. If you use a nebuliser, airway clearance device or oxygen concentrator, check the airline's rules well before departure.

Bring imaging on disc, not only reports. This matters more in respiratory medicine than in most specialties, because a second reader's value lies in seeing the scan rather than reading somebody's description of it.

On payment, ask what the quotation includes and excludes, what happens if additional tests are needed, and what is refundable if a procedure is cancelled on medical grounds. Pay into the hospital's official account named in the contract, never into an individual's account, and keep receipts for everything.

Arrange the return before you leave: who reviews the results at home, who receives the report, and what the plan is if something changes while you are away.

The clinical risks of the procedures discussed here belong on the pages that describe them. What belongs on this page are the risks that come from doing this far from home, and from pursuing something that is not available.

The first is opportunity cost, and in advanced lung disease it is the most serious. Time spent chasing a transplant that cannot happen is time not spent on antifibrotic treatment, rehabilitation, or remaining listed at home. Lung disease progresses, and a delay of months is not neutral.

The second is discontinuity. Assessment produces results, and results need acting on. If a Turkish team recommends a change in treatment, somebody at home has to implement and monitor it. Establish who that is before you travel, and make sure they will receive the report directly rather than via you.

The third is fraud. Anybody promising a lung transplant in Türkiye to a foreign patient is either uninformed or exploiting you. The pattern repeats: assurances by phone or messaging, a price before any clinician has read the records, a large payment requested up front, and a refusal to put anything in writing.

The fourth is the risk of travelling while too unwell. Advanced lung disease and long flights combine badly, and the calculation is not the same as for a healthier traveller. A trip that would be reasonable for somebody stable can be genuinely dangerous for somebody deteriorating, and this should be assessed honestly rather than optimistically.

None of this argues against seeking expert help abroad. It argues for seeking the right thing, with your own physician's agreement, having verified what you were told.